[VIRTUAL] GLOBAL RATES OF INFLUENZA (FV) AND PNEUMOCOCCAL (PV) VACCINATION IN MULTIPLE MYELOMA (MM) PATIENTS (PTS) IN INSIGHT MM: IMPACT ON HEALTHCARE RESOURCE UTILIZATION (HRU) AND OVERALL SURVIVAL (OS)

[VIRTUAL] UPDATED RESULTS FROM BELLINI, A PHASE 3 STUDY OF VENETOCLAX OR PLACEBO IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

[VIRTUAL] OPTIMISMM SUBANALYSIS: POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS

[VIRTUAL] IMPACT OF PREMATURE VENETOCLAX (VEN) DISCONTINUATION/INTERRUPTION ON OUTCOMES IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS FROM THE PHASE III MURANO STUDY

[VIRTUAL] MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

[VIRTUAL] HEALTH-RELATED QUALITY OF LIFE IN HEAVILY PRE-TREATED AND RENALLY IMPAIRED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE: ICARIA-MM STUDY

[VIRTUAL] BASELINE AND POSTINFUSION PHARMCODYNAMIC BIOMARKERS OF SAFETY AND EFFICACY IN PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) IN THE KARMMA STUDY

[VIRTUAL] SAFETY AND ACTIVITY OF THE ONCE DAILY SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR TG-1701 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND LYMPHOMA.

[VIRTUAL] DASATINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND SUBOPTIMAL RESPONSES TO 3 MONTHS OF IMATINIB THERAPY: 3-YEAR EXTENDED FOLLOW-UP (FU) FROM DASCERN

[VIRTUAL] PHASE 1/2 STUDY OF SINGLE-AGENT ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

[VIRTUAL] UPDATED RESULTS OF THE ASPEN TRIAL FROM A COHORT OF PATIENTS WITH MYD88 WILD-TYPE WALDENSTRÖM MACROGLOBULINEMIA

[VIRTUAL] EVALUATION OF MINIMAL RESIDUAL DISEASE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH VENETOCLAX OR PLACEBO IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE: BELLINI STUDY ANALYSES

[VIRTUAL] HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES, ACUTE MYELOID LEUKEMIA, AND CHRONIC MYELOMONOCYTIC LEUKEMIA RECEIVING GLASDEGIB + AZACITIDINE.

[VIRTUAL] RETROSPECTIVE INDEPENDENT REVIEW OF ARTERIAL OCCLUSIVE EVENTS (AOES) IN THE PHASE 2 PACE TRIAL OF PONATINIB IN PHILADELPHIA CHROMOSOME POSITIVE (PH+) LEUKEMIA

[VIRTUAL] A RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE EFFECTS OF PEVONEDISTAT ON THE QTC INTERVAL IN PATIENTS WITH ADVANCED MALIGNANCIES